De Phung

5.9k citations

46 papers · 2.0k indexed · 1 hit paper · h-index 19

Impact in

Pulmonary and Respiratory Medicine top 1%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Cancer Research top 5%
- Cancer, Lipids, and Metabolism

Papers in ⓘ

Pulmonary and Respiratory Medicine 44
- Prostate Cancer Treatment and Research 44
- Prostate Cancer Diagnosis and Treatment 7
Radiology, Nuclear Medicine and Imaging 26
- Radiopharmaceutical Chemistry and Applications 26

Co-authors: Andrew Krivoshik (9 shared papers)Neal D. Shore (8 shared papers)Cora N. Sternberg (17 shared papers)Karim Fizazi (12 shared papers)Per Rathenborg (8 shared papers)Fred Saad (11 shared papers)Katharina Modelska (5 shared papers)Maha Hussain (5 shared papers)
Journals: Journal of Clinical Oncology (23 papers)The Journal of Urology (3 papers)The Lancet Oncology (3 papers)Clinical Genitourinary Cancer (2 papers)European Urology (2 papers)
Partner nations: United States Netherlands United Kingdom

In The Last Decade

De Phung

45 papers receiving 2.0k citations

Hit Papers

align trajectories log scale

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer 2018 · 677 citations

Peers

Countries citing papers authored by De Phung

Since Specialization

Citations

This map shows the geographic impact of De Phung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by De Phung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites De Phung more than expected).

Fields of papers citing papers by De Phung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by De Phung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by De Phung. The network helps show where De Phung may publish in the future.

Co-authors

The 25 scholars most cited alongside De Phung, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with De Phung Line = papers co-authored together De Phung links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer New England Journal of Medicine ·Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal D. Shore, Ubirajara Ferreira, Petro Ivashchenko, Eren Demirhan, Katharina Modelska, De Phung, Andrew Krivoshik, Cora N. Sternberg Hit paper breakdown →	2018	677
2	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial Journal of Clinical Oncology ·David F. Penson, Andrew J. Armstrong, Raoul S. Concepcion, Neeraj Agarwal, Carl A. Olsson, Lawrence I. Karsh, Curtis Dunshee, Fong Wang, Kenneth K. Wu, Andrew Krivoshik, De Phung, Celestia S. Higano	2016	223
3	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study The Lancet Oncology ·Neal D. Shore, Simon Chowdhury, Arnauld Villers, Laurence Klotz, D. Robert Siemens, De Phung, Steve van Os, Nahla Hasabou, Fong Wang, Suman Bhattacharya, Axel Heidenreich	2016	185
4	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial The Lancet Oncology ·Yohann Loriot, Kurt Miller, Cora N. Sternberg, Karim Fizazi, Johann S. de Bono, Simon Chowdhury, Celestia S. Higano, Sarah B. Noonberg, Stefan Holmström, Harry H. Mansbach, Frank Perabo, De Phung, Cristina Ivanescu, Konstantina Skaltsa, Tomasz M. Beer, Bertrand Tombal	2015	140
5	Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial European Urology ·Nicholas D. James, Armelle Caty, Michael Borre, Bernard A. Zonnenberg, Philippe Beuzeboc, Thomas Morris, De Phung, Nancy A. Dawson	2008	137
6	Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration‐resistant prostate cancer and bone metastases who were pain‐free or mildly symptomatic for pain: a double‐blind, placebo‐controlled, randomized Phase II trial British Journal of Urology ·Nicholas D. James, Armelle Caty, Heather Payne, Michael Borre, Bernard A. Zonnenberg, Philippe Beuzeboc, Stuart McIntosh, Thomas Morris, De Phung, Nancy A. Dawson	2010	88
7	Postherpetic Neuralgia: Impact of Famciclovir, Age, Rash Severity, and Acute Pain in Herpes Zoster Patients The Journal of Infectious Diseases ·Robert H. Dworkin, Ron Boon, David R. G. Griffin, De Phung	1998	80
8	Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study The Lancet Oncology ·Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiří Heráček, Edwina Baskin-Bey, Taoufik Ouatas, Frank Perabo, De Phung, Mohammad Hirmand, Matthew R. Smith	2014	71
9	Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results European Urology ·Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiří Heráček, Edwina Baskin-Bey, Taoufik Ouatas, Frank Perabo, De Phung, Benoît Baron, Mohammad Hirmand, Matthew R. Smith	2015	34
10	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer JAMA Oncology ·Dana E. Rathkopf, Tomasz M. Beer, Yohann Loriot, Celestia S. Higano, Andrew J. Armstrong, Cora N. Sternberg, Johann S. de Bono, Bertrand Tombal, Teresa Parli, Suman Bhattacharya, De Phung, Andrew Krivoshik, Howard I. Scher, Michael J. Morris	2018	34
11	Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel Cancer ·Andrew J. Armstrong, Fred Saad, De Phung, Carl Dmuchowski, Neal D. Shore, Karim Fizazi, Mohammad Hirmand, David Forer, Howard I. Scher, Johann S. de Bono	2017	31
12	The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies European Journal of Cancer ·Tomasz M. Beer, Kurt Miller, Bertrand Tombal, David Cella, De Phung, Stefan Holmström, Cristina Ivanescu, Konstantina Skaltsa, Shevani Naidoo	2017	29
13	Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·Eleni Efstathiou, Mark Titus, Sijin Wen, Aileen SanMiguel, Anh Hoang, Angela De Haas-Amatsaleh, Frank Perabo, De Phung, Patricia Troncoso, Taoufik Ouatas, Christopher J. Logothetis	2014	29
14	PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). Journal of Clinical Oncology ·Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal D. Shore, Eren Demirhan, Katharina Modelska, De Phung, Andrew Krivoshik, Cora N. Sternberg	2018	26
15	Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial European Urology Oncology ·Andrew J. Armstrong, Ping Lin, Celestia S. Higano, Peter Iversen, Cora N. Sternberg, Bertrand Tombal, De Phung, Teresa Parli, Andrew Krivoshik, Tomasz M. Beer	2018	25
16	A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer Investigational New Drugs ·William R. Schelman, Glenn Liu, George Wilding, Thomas Morris, De Phung, Robert Dreicer	2009	24
17	Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial Clinical Genitourinary Cancer ·Joshi J. Alumkal, Simon Chowdhury, Yohann Loriot, Cora N. Sternberg, Johann S. de Bono, Bertrand Tombal, Joan Carles, Thomas W. Flaig, Tanya B. Dorff, De Phung, David Forer, Sarah B. Noonberg, Hank Mansbach, Tomasz M. Beer, Celestia S. Higano	2017	24
18	Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial Health and Quality of Life Outcomes ·Nancy Devlin, Michael Herdman, Marco Pavesi, De Phung, Shevani Naidoo, Tomasz M. Beer, Bertrand Tombal, Yohann Loriot, Cristina Ivanescu, Teresa Parli, Mark Balk, Stefan Holmström	2017	24
19	Mapping the FACT-P to the Preference-Based EQ-5D Questionnaire in Metastatic Castration-Resistant Prostate Cancer Value in Health ·Konstantina Skaltsa, Louise Longworth, Cristina Ivanescu, De Phung, Stefan Holmström	2014	21
20	Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). Journal of Clinical Oncology ·Matthew R. Smith, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Edwina Baskin-Bey, Frank Perabo, De Phung, Bertrand Tombal	2013	12

About De Phung

De Phung is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Cancer Research, Oncology and Endocrinology, Diabetes and Metabolism, having authored 46 papers that have together received 2.0k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (44 papers), Radiopharmaceutical Chemistry and Applications (26 papers), Cancer, Lipids, and Metabolism (17 papers), Cancer Treatment and Pharmacology (9 papers), Hormonal and reproductive studies (7 papers), Prostate Cancer Diagnosis and Treatment (7 papers), Bone health and treatments (4 papers) and Multiple Myeloma Research and Treatments (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.7k citations), Cancer Research (612 citations), Radiology, Nuclear Medicine and Imaging (618 citations), Endocrinology, Diabetes and Metabolism (357 citations) and Oncology (495 citations). De Phung has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Andrew Krivoshik, Neal D. Shore, Cora N. Sternberg, Karim Fizazi, Per Rathenborg, Fred Saad, Katharina Modelska, Maha Hussain, Eren Demirhan and Ubirajara Ferreira. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Urology, The Lancet Oncology, Clinical Genitourinary Cancer and European Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact